BioLineRx Ltd. (BLRX)
- Previous Close
0.5753 - Open
0.5614 - Bid 0.5843 x 100
- Ask 0.6343 x 100
- Day's Range
0.5528 - 0.6216 - 52 Week Range
0.5528 - 2.5300 - Volume
581,327 - Avg. Volume
422,187 - Market Cap (intraday)
56.315M - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.75
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
www.biolinerx.comRecent News: BLRX
Performance Overview: BLRX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLRX
Valuation Measures
Market Cap
52.97M
Enterprise Value
21.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.70
Price/Book (mrq)
3.48
Enterprise Value/Revenue
4.49
Enterprise Value/EBITDA
-0.38
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.30%
Return on Equity (ttm)
-189.23%
Revenue (ttm)
4.8M
Net Income Avi to Common (ttm)
-60.61M
Diluted EPS (ttm)
-0.9000
Balance Sheet and Cash Flow
Total Cash (mrq)
42.99M
Total Debt/Equity (mrq)
87.66%
Levered Free Cash Flow (ttm)
-9.6M